This P50 application is for the renewal of the Mayo SPORE In Brain Cancer for years 6-10. The SPORE will support a multidisciplinary team of basic and applied science investigators to perform translational research directed at significantly reducing morbidity and mortality from malignant gliomas. Brian Patrick O'Neill, M.D. will serve as Overall Principal Investigator and Director of the Administrative Core. Robert B. Jenkins, M.D., Ph.D. will serve as Overall Co-Principal Investigator and Administrative Core Co-Director. The translational research objectives of the SPORE will be directed by 14 investigators from 8 departments at Mayo Clinic in Rochester, all with a demonstrable history of collaborative and translational research. The SPORE comprises 4 Mayo investigator- initiated research projects and 4 scientific core resources consolidated by the Administrative Core. The SPORE also includes career development and developmental research programs. SPORE Research Projects 1. Influence of DNA repair on PARP inhibitor efficacy In GBM (Co-Leaders: J.N. Sarkaria, M.D., and N. Laack, M.D.) 2. Optimizing Measles Virotherapy In the Treatment of Gliomas (Co-Leaders: E. Galanis, M.D., D.Sc. and I.F. Parney, M.D., Ph.D.) 3. The Role of MMSET in DNA damage response and chemoradioresistance of glioblastoma (Co-Leaders: Z. Lou, Ph.D. and J. C. Buckner, M.D.) 4. Clinical Relevance of Chromosome 5p/9p/20q/8q Germline Alterations In Glioma (Co-Leaders: R. B. Jenkins, M.D., Ph.D and P. Yang, M.D., Ph.D. SPORE Scientific Cores A. Administrative Core (Director: B. P. O'Neill, M.D.;Co-Director: R.B. Jenkins, M.D., Ph.D.) B. Biostatistics Core (Director: K.V. Ballman, Ph.D.;Co-Director: W. Wu, Ph.D.) C. Pathology and Tissue Procurement Core (Director: C. Giannini, M.D., Ph.D.;Co-Director: F. Rodriguez, M.D.) D. Animal Core (Director: J.N. Sarkaria, M.D.;Co-Director: I.F. Parney, M.D., Ph.D.) E. Clinical Research Core (Director: J.C. Buckner, M.D.;Co-Director: D. H. Lachance, M.D.) Developmental Research Portfolio

Public Health Relevance

Compared to other more common cancers malignant gliomas are responsible for a disproportionate amount of morbidity and mortality because of their disabling impact on cognition, memory, language, mobility, and adaptive skills. In addition to significant reduction in life expectancy each new malignant gliomas case impacts the nation's public health since its morbidity represents on average twenty years of lost productivity. Whether the payer is public or private, diagnosis and treatment, including supportive care in the terminal stages of disease, extracts enormous health care expenditures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-08
Application #
8535534
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Arnold, Julia T
Project Start
2004-09-20
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$2,084,586
Indirect Cost
$772,575
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Oi, N; Yuan, J; Malakhova, M et al. (2015) Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene 34:2660-71
Choi, Jae Won; Schroeder, Mark A; Sarkaria, Jann N et al. (2014) Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells. Cancer Res 74:484-96
Bradley, Barrie S; Loftus, Joseph C; Mielke, Clinton J et al. (2014) Differential expression of microRNAs as predictors of glioblastoma phenotypes. BMC Bioinformatics 15:21
Walsh, Kyle M; Codd, Veryan; Smirnov, Ivan V et al. (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731-5
Bell, Michael P; Renner, Danielle N; Johnson, Aaron J et al. (2014) An elite controller of picornavirus infection targets an epitope that is resistant to immune escape. PLoS One 9:e94332
Catteau, Aurélie; Girardi, Hélène; Monville, Florence et al. (2014) A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun 2:58
Johnson, Holly L; Jin, Fang; Pirko, Istvan et al. (2014) Theiler's murine encephalomyelitis virus as an experimental model system to study the mechanism of blood-brain barrier disruption. J Neurovirol 20:107-12
Gupta, Shiv K; Mladek, Ann C; Carlson, Brett L et al. (2014) Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 20:3730-41
Assefnia, Shahin; Dakshanamurthy, Sivanesan; Guidry Auvil, Jaime M et al. (2014) Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget 5:1458-74
Wang, Enfeng; Zhang, Chunyang; Polavaram, Navatha et al. (2014) The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PLoS One 9:e86102

Showing the most recent 10 out of 103 publications